S100A1 and ovarian cancer: DeRycke MS’s report indicated that S100A1 mRNA and protein expression elevated with increasing Silverberg grade but not stage in serous ovarian cancer, while in endometrial subtype of ovarian cancer, there was no correlation between S100A1 expression and clinical stage or grade, but it was related with decreased relapse-free survival (RFS) [6].